When small becomes big: The new challenges of orphan drugs in Europe

Top Quote The orphan drug landscape is quickly becoming a commercially attractive market. End Quote
  • (1888PressRelease) January 24, 2017 - Throughout the years the European pharmaceutical landscape has undergone a significant shift, resulting in an increasing acknowledgment of specialty medicines and diseases with lesser patient population.

    The orphan drugs landscape has become a commercially attractive market as a result of vigorous patient advocacy, medical breakthroughs, regulatory incentives and venture capital investment.

    This year's 6th annual Orphan Drugs and Rare Diseases Europe conference will deliver an in-depth overview of the regulatory landscape, pricing strategy and orphan drug development over two days.

    Bertram Haussler, Chairman of the Board of Management, IGES Institut will be presenting the host nation address, which will be focused on active measures to improve the health situation of those living with rare diseases in Germany.

    Some of the topical areas of discussion will include regulatory developments, strategies for best route to market, pricing and reimbursement concerns including the controversial German pricing mechanism. Other conference highlights to expect this year will include:
    SIX spotlight sessions
    Opening keynote from Alexion Pharma
    Host nation address from IGES Institut
    TWO interactive post conference workshops
    Topical panel discussion from Global Market Access Solutions, Agerion Pharmaceuticals, RBV Capital
    FIVE+ hours of networking opportunities with senior industry professionals
    Global drug market case studies from Italy, Middle East, Greece & the UK

    Visit www.orphandrugs-event.com/1888 for more information or to view the complete two day agenda.

    There is currently a 400 early bird discount for all bookings made before 31st January.

    Orphan Drugs and Rare Diseases Europe 2017
    15th - 16th May 2017
    Berlin, Germany
    Follow the conversation on Twitter and LinkedIn at #smiorphandrugseurope

  • FB Icon Twitter Icon In-Icon
Contact Information